Suppr超能文献

替加色罗与胃动素受体激动剂在体外刺激胃动力能力上的差异。

Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro.

作者信息

Jarvie E M, North Laidler V J, Corcoran S, Bassil A, Sanger G J

机构信息

Neurology & Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Limited, New Frontiers Science Park, Harlow, Essex UK.

出版信息

Br J Pharmacol. 2007 Feb;150(4):455-62. doi: 10.1038/sj.bjp.0707118. Epub 2007 Jan 8.

Abstract

BACKGROUND AND PURPOSE

Motilin or 5-HT4 receptor agonists stimulate gastrointestinal motility. Differences in activity are suggested but direct comparisons are few. A method was devised to directly compare the gastric prokinetic activities of motilin, the motilin receptor agonist, erythromycin, and the 5-HT4 receptor agonist, tegaserod.

EXPERIMENTAL APPROACH

Gastric prokinetic-like activity was assessed by measuring the ability to facilitate cholinergically-mediated contractions evoked by electrical field stimulation (EFS) in rabbit isolated stomach. Comparisons were made between potency, maximal activity and duration of responses.

KEY RESULTS

Rabbit motilin (r.motilin) 0.003-0.3 microM, [Nle13]motilin 0.003-0.3 microM, erythromycin 0.3-10 microM and tegaserod 0.1-10 microM caused concentration - dependent potentiation of EFS-evoked contractions. The potency ranking was r.motilin = [Nle13]motilin > tegaserod > erythromycin. The Emax ranking was r.motilin = [Nle13]motilin = erythromycin > tegaserod. Responses to r.motilin and [Nle13]motilin faded rapidly (t1/2 9 and 11 min, respectively) whereas those to erythromycin and tegaserod were maintained longer (t1/2 24 and 28 min). The difference did not appear to be due to peptide degradation. A second application of [Nle13]motilin was excitatory after 60 min contact and fade of the initial response (responses to 0.03 and 0.1 microM [Nle13]motilin were not different from those caused by the first application).

CONCLUSIONS AND IMPLICATIONS

Prokinetic-like activities of the 5-HT4 agonist tegaserod and the motilin receptor agonists were compared by measuring changes in cholinergically-mediated contractions. This novel approach highlighted important differences between classes (greater Emax of motilin, compared with tegaserod) and for the first time, within each class (short t1/2 for motilin, compared with erythromycin).

摘要

背景与目的

胃动素或5 - HT4受体激动剂可刺激胃肠动力。虽有研究表明它们的活性存在差异,但直接比较却很少。本研究设计了一种方法,用于直接比较胃动素、胃动素受体激动剂红霉素以及5 - HT4受体激动剂替加色罗的促胃动力活性。

实验方法

通过测量电场刺激(EFS)诱发的胆碱能介导收缩的促进能力,评估兔离体胃中的促胃动力样活性。比较了效价、最大活性和反应持续时间。

主要结果

兔胃动素(r.motilin)0.003 - 0.3微摩尔/升、[Nle13]胃动素0.003 - 0.3微摩尔/升、红霉素0.3 - 10微摩尔/升和替加色罗0.1 - 10微摩尔/升均引起EFS诱发收缩的浓度依赖性增强。效价排序为r.motilin = [Nle13]胃动素>替加色罗>红霉素。最大效应(Emax)排序为r.motilin = [Nle13]胃动素 = 红霉素>替加色罗。对r.motilin和[Nle13]胃动素的反应迅速消退(半衰期分别为9分钟和11分钟),而对红霉素和替加色罗的反应维持时间更长(半衰期分别为24分钟和28分钟)。这种差异似乎并非由于肽降解所致。在最初反应消退60分钟后,再次应用[Nle13]胃动素具有兴奋性(对0.03和0.1微摩尔/升[Nle13]胃动素的反应与首次应用时无差异)。

结论与意义

通过测量胆碱能介导收缩的变化,比较了5 - HT4激动剂替加色罗和胃动素受体激动剂的促胃动力样活性。这种新方法突出了不同类别之间的重要差异(与替加色罗相比,胃动素的Emax更大),并且首次在每个类别内部发现了差异(与红霉素相比,胃动素的半衰期较短)。

相似文献

1
Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro.
Br J Pharmacol. 2007 Feb;150(4):455-62. doi: 10.1038/sj.bjp.0707118. Epub 2007 Jan 8.
2
GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility.
Neurogastroenterol Motil. 2009 Jun;21(6):657-64, e30-1. doi: 10.1111/j.1365-2982.2008.01270.x.
3
The rabbit motilin receptor: molecular characterisation and pharmacology.
Br J Pharmacol. 2003 Nov;140(5):948-54. doi: 10.1038/sj.bjp.0705505. Epub 2003 Sep 22.
5
RQ-00201894: A motilin receptor agonist causing long-lasting facilitation of human gastric cholinergically-mediated contractions.
J Pharmacol Sci. 2016 Feb;130(2):60-5. doi: 10.1016/j.jphs.2015.11.004. Epub 2015 Nov 19.
6
The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.
Br J Pharmacol. 2004 Nov;143(5):549-60. doi: 10.1038/sj.bjp.0705929. Epub 2004 Oct 4.

引用本文的文献

1
Structural basis for motilin and erythromycin recognition by motilin receptor.
Sci Adv. 2023 Mar 17;9(11):eade9020. doi: 10.1126/sciadv.ade9020. Epub 2023 Mar 15.
2
Effects of Motilin Receptor Agonists and Ghrelin in Human Transgenic Mice.
Int J Mol Sci. 2019 Mar 27;20(7):1521. doi: 10.3390/ijms20071521.
4
Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.
Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):38-48. doi: 10.1038/nrgastro.2015.163. Epub 2015 Sep 22.
7
Translational neuropharmacology: the use of human isolated gastrointestinal tissues.
Br J Pharmacol. 2013 Jan;168(1):28-43. doi: 10.1111/j.1476-5381.2012.02198.x.
8
Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists.
Br J Pharmacol. 2012 Oct;167(4):763-74. doi: 10.1111/j.1476-5381.2012.02009.x.
9
The hungry stomach: physiology, disease, and drug development opportunities.
Front Pharmacol. 2011 Feb 18;1:145. doi: 10.3389/fphar.2010.00145. eCollection 2010.
10
Colitis affects the smooth muscle and neural response to motilin in the rabbit antrum.
Br J Pharmacol. 2010 Jan 1;159(2):384-93. doi: 10.1111/j.1476-5381.2009.00537.x. Epub 2009 Dec 4.

本文引用的文献

1
Effect of atilmotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study.
Neurogastroenterol Motil. 2006 Jan;18(1):28-36. doi: 10.1111/j.1365-2982.2005.00726.x.
2
Prokineticin-2, motilin, ghrelin and metoclopramide: prokinetic utility in mouse stomach and colon.
Eur J Pharmacol. 2005 Nov 7;524(1-3):138-44. doi: 10.1016/j.ejphar.2005.09.007. Epub 2005 Oct 19.
3
Characterization of agonist-induced motilin receptor trafficking and its implications for tachyphylaxis.
Mol Pharmacol. 2006 Jan;69(1):109-18. doi: 10.1124/mol.105.017111. Epub 2005 Oct 12.
4
Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor.
Biochem Pharmacol. 2005 Sep 15;70(6):879-87. doi: 10.1016/j.bcp.2005.06.022.
5
The use of long-term, low-dose erythromycin in treating persistent gastric stasis.
J Pain Symptom Manage. 2005 May;29(5):430-3. doi: 10.1016/j.jpainsymman.2005.03.004.
6
Desensitization of the human motilin receptor by motilides.
J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405. doi: 10.1124/jpet.104.081497. Epub 2005 Mar 11.
7
The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.
Br J Pharmacol. 2004 Nov;143(5):549-60. doi: 10.1038/sj.bjp.0705929. Epub 2004 Oct 4.
8
Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis.
J Clin Gastroenterol. 2004 Mar;38(3):237-42. doi: 10.1097/00004836-200403000-00008.
9
The rabbit motilin receptor: molecular characterisation and pharmacology.
Br J Pharmacol. 2003 Nov;140(5):948-54. doi: 10.1038/sj.bjp.0705505. Epub 2003 Sep 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验